Literature DB >> 27916995

Prevention of Muscle Wasting by CRISPR/Cas9-mediated Disruption of Myostatin In Vivo.

Yuda Wei1, Yanhao Chen1, Yan Qiu1, Huan Zhao1, Gaigai Liu1, Yongxian Zhang1, Qingyang Meng2, Guohao Wu2, Yixiong Chen3, Xiaolong Cai3, Hui Wang4, Hao Ying4, Bin Zhou1, Mingyao Liu5, Dali Li5, Qiurong Ding6.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27916995      PMCID： PMC5154488          DOI： 10.1038/mt.2016.192

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  10 in total

1.  Myostatin mutation associated with gross muscle hypertrophy in a child.

Authors:  Markus Schuelke; Kathryn R Wagner; Leslie E Stolz; Christoph Hübner; Thomas Riebel; Wolfgang Kömen; Thomas Braun; James F Tobin; Se-Jin Lee
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

2.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.

Authors:  Chengzu Long; Leonela Amoasii; Alex A Mireault; John R McAnally; Hui Li; Efrain Sanchez-Ortiz; Samadrita Bhattacharyya; John M Shelton; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

4.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells.

Authors:  Mohammadsharif Tabebordbar; Kexian Zhu; Jason K W Cheng; Wei Leong Chew; Jeffrey J Widrick; Winston X Yan; Claire Maesner; Elizabeth Y Wu; Ru Xiao; F Ann Ran; Le Cong; Feng Zhang; Luk H Vandenberghe; George M Church; Amy J Wagers
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

5.  Construction and analysis of compact muscle-specific promoters for AAV vectors.

Authors:  B Wang; J Li; F H Fu; C Chen; X Zhu; L Zhou; X Jiang; X Xiao
Journal:  Gene Ther       Date:  2008-06-19       Impact factor: 5.250

Review 6.  Muscle wasting in disease: molecular mechanisms and promising therapies.

Authors:  Shenhav Cohen; James A Nathan; Alfred L Goldberg
Journal:  Nat Rev Drug Discov       Date:  2015-01       Impact factor: 84.694

7.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

Review 8.  Genome-editing Technologies for Gene and Cell Therapy.

Authors:  Morgan L Maeder; Charles A Gersbach
Journal:  Mol Ther       Date:  2016-01-12       Impact factor: 11.454

9.  Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.

Authors:  Nicole Ebner; Lisa Steinbeck; Wolfram Doehner; Stefan D Anker; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-03-05       Impact factor: 12.910

10.  Paracrine and endocrine modes of myostatin action.

Authors:  Yun-Sil Lee; Thanh V Huynh; Se-Jin Lee
Journal:  J Appl Physiol (1985)       Date:  2016-01-14
  10 in total
  9 in total

1.  Editorial: Geriatrics in the 21st Century.

Authors:  B Vellas; J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

2.  CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice.

Authors:  Jin Li; Lijun Wang; Xuejiao Hua; Haifei Tang; Rui Chen; Tingting Yang; Saumya Das; Junjie Xiao
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

Review 3.  Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.

Authors:  Valentina Colapicchioni; Francesco Millozzi; Ornella Parolini; Daniela Palacios
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-29

Review 4.  Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.

Authors:  Peter Gee; Huaigeng Xu; Akitsu Hotta
Journal:  Stem Cells Int       Date:  2017-05-15       Impact factor: 5.443

5.  Treatment of sarcopenia: the road to the future.

Authors:  John E Morley
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-12       Impact factor: 12.910

6.  Angiotensin (1-7) Decreases Myostatin-Induced NF-κB Signaling and Skeletal Muscle Atrophy.

Authors:  Javier Aravena; Johanna Abrigo; Francisco Gonzalez; Francisco Aguirre; Andrea Gonzalez; Felipe Simon; Claudio Cabello-Verrugio
Journal:  Int J Mol Sci       Date:  2020-02-10       Impact factor: 5.923

Review 7.  A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives.

Authors:  Dorota Skrzypczak; Alicja Ewa Ratajczak; Aleksandra Szymczak-Tomczak; Agnieszka Dobrowolska; Piotr Eder; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2021-01-20       Impact factor: 5.717

8.  Construction of a rAAV-SaCas9 system expressing eGFP and its application to improve muscle mass.

Authors:  Shaoting Weng; Yitian Zhao; Changhong Yu; Xiaofan Wang; Xuehan Xiao; Liqiang Han; Kunpeng Zhang; Jiang Wang; Guoyu Yang
Journal:  Biotechnol Lett       Date:  2021-09-29       Impact factor: 2.461

9.  Improvement of muscular atrophy by AAV-SaCas9-mediated myostatin gene editing in aged mice.

Authors:  Shaoting Weng; Feng Gao; Juan Wang; Xingyu Li; Beibei Chu; Jiang Wang; Guoyu Yang
Journal:  Cancer Gene Ther       Date:  2020-05-13       Impact factor: 5.987
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.